WEST

Help | Logout | Interrupt

Main Menu | Search Form | Posting Counts | Show S Numbers | Edit S Numbers | Preferences | Cases

Search Results -

Terms	Documents
l26 with l4	3

Database: US Patents Full-Text Database
US Pre-Grant Publication Full-Text Database
JPO Abstracts Database
EPO Abstracts Database
Derwent World Patents Index
IBM Technical Disclosure Bulletins

Search: L31

Refine Search

Recall Text | Clear

Search History

DATE: Monday, July 14, 2003 Printable Copy Create Case

Set Name side by side	Query	Hit Count	Set Name result set
DB=USPT,PGPB,JPAB,EPAB,DWPI; PLUR=YES; OP=ADJ			
L31	l26 with l4	3	L31
L30	l26 same l4	3	L30
L29	L28 and l4	4	L29
L28	L27 with l26	50	L28
L27	lung or pneumo$	103405	L27
L26	Rhino$ with equine	381	L26
L25	rhinopnem$	1	L25
L24	l22 same l4	4	L24
L23	L22 and l4	76	L23
L22	equine with influenza	587	L22
L21	equine with influenze	6	L21
L20	L19 and l4	27	L20
L19	L18 with l17	220	L19
L18	equine	8806	L18
L17	EHV or EIV	776	L17
L16	L15 same l2	16	L16
L15	copolymer with ema	1441	L15
L14	L13 and l4	20	L14
L13	L12 with l2	195	L13
L12	carbopol	7940	L12
L11	l10 and l4	9	L11
L10	L9 with l7	97	L10
L9	carbomer or EMA	9644	L9
L8	L7 and l1	23	L8
L7	antigen or vaccine or immunogen	121351	L7
L6	l4 and l1	6	L6
L5	l4 same l1	1	L5
L4	dna vaccine or gene delivery	6685	L4
L3	L2 same l1	19	L3
L2	adjuvant	77886	L2
L1	maleic anhydride with alkenyl	1389	L1

END OF SEARCH HISTORY

palmintra.gif (12870 bytes)

Day : Monday
Date: 7/14/2003
Time: 16:42:33

Application Number Information

Application Number: **09/912552**
Assignments
Filing Date: **07/23/2001**
Effective Date: **07/23/2001**
Application Received: **07/26/2001**
Pat. Num./Pub. Num: **/20020187553**
Issue Date: **00/00/0000**
Date of Abandonment: **00/00/0000**
Attorney Docket Number: **3935.1US**
Status: **61 /FINAL REJECTION MAILED**
Confirmation Number: **4762**

Examiner Number: **72603 / PRIEBE, SCOTT**
Group Art Unit: **1632**
Class/Subclass: **435/325.000**
Lost Case: **NO**
Interference Number:
Unmatched Petition: **NO**
L&R Code: Secrecy Code:**1**
Third Level Review: **NO**
Oral Hearing: **NO**

Waiting for Response Desc.
Mail Final Rej.

Secrecy Order: **NO**
Status Date: **05/08/2003**

Title of Invention: **PACKAGING SYSTEMS FOR HUMAN RECOMBINANT ADENOVIRUS TO BE USED IN GENE THERAPY**

Bar Code	PALM Location	Location Date	Charge to Loc	Charge to Name	Employee Name	Location
09912552	16C1	07/14/2003	16G6	No Charge to Name	NORFLEET,CASSIUS	CM1/11/C 10

Appln Info | Contents | Petition Info | Atty/Agent Info | Continuity Data | Foreign Data | Invent

Search Another: Application# [ ] Search **or Patent#** [ ] Search

PCT / [ ] / [ ] Search **or PG PUBS #** [ ] Search

Attorney Docket # [ ] Search

Bar Code # [ ] Search

To go back use Back button on your browser toolbar.

Back to PALM | ASSIGNMENT | OASIS | Home page

WEST

Generate Collection Print

L14: Entry 14 of 20 File: USPT Oct 29, 2002

US-PAT-NO: 6472183
DOCUMENT-IDENTIFIER: US 6472183 B2

TITLE: Immunity against Actinobacillus pleuropneumoniae's RTX toxins APX

DATE-ISSUED: October 29, 2002

US-CL-CURRENT: 435/71.1; 424/184.1, 424/234.1, 424/235.1, 424/236.1, 435/243, 435/252.3, 435/252.8, 435/320.1, 435/471, 435/69.1, 435/69.3, 435/69.7, 536/23.1, 536/23.7

APPL-NO: 09/ 068086 [PALM]
DATE FILED: June 19, 1998

FOREIGN-APPL-PRIORITY-DATA:

COUNTRY	APPL-NO	APPL-DATE
AU	PN 6314	November 2, 1995

PCT-DATA:

APPL-NO	DATE-FILED	PUB-NO	PUB-DATE	371-DATE	102(E)-DATE
PCT/AU96/00686	November 1, 1996	WO97/16532	May 9, 1997	Jun 19, 1998	Jun 19, 1998

US 20030003112A1

(19) United States

(12) Patent Application Publication (10) Pub. No.: US 2003/0003112 A1

Audonnet et al. (43) Pub. Date: Jan. 2, 2003

(54) PORCINE REPRODUCTIVE AND RESPIRATORY SYNDROME VIRUS (PRRSV) RECOMBINANT POXVIRUS VACCINE

(76) Inventors: Jean-Christophe Audonnet, Lyon (FR); Michel Bublot, Delmar, NY (US); Jennifer Perez, Worcester, MA (US); Philippe Baudu, Craponne (FR)

Correspondence Address:
Thomas J. Kowalski
FROMMER LAWRENCE & HAUG LLP
745 Fifth Avenue
New York, NY 10151 (US)

(21) Appl. No.: 09/862,393

(22) Filed: May 21, 2001

Related U.S. Application Data

(60) Provisional application No. 60/206,655, filed on May 24, 2000.

Publication Classification

(51) Int. Cl.[7] A61K 39/285; A61K 39/275; C12N 7/00

(52) U.S. Cl. 424/232.1; 424/186.1; 435/235.1

(57) ABSTRACT

What is described is a recombinant vector, such as a virus; for instance, a poxvirus, such as avipox virus, containing foreign DNA from porcine reproductive and respiratory syndrome virus. What are also described are immunological compositions containing the recombinant poxvirus for inducing an immunological response in a host animal to which the immunological composition is administered. Also described are methods of treating or preventing disease caused by porcine reproductive and respiratory syndrome virus by administering the immunological compositions of the invention to an animal in need of treatment or susceptible to infection by porcine reproductive and respiratory syndrome virus.

L16: Entry 4 of 16 File: USPT Oct 9, 2001

DOCUMENT-IDENTIFIER: US 6300118 B1
TITLE: Plasmids comprising a genetically altered feline immunodeficiency virus genome

Detailed Description Text (7):
Typically, the concentration of virus in the vaccine formulation will be a minimum of 10.sup.6.0 virus particles per dose, but will typically be in the range of 10.sup.6.0 to 10.sup.8.0 virus particles per dose. At the time of vaccination, the virus is thawed (if frozen) or reconstituted (if lyophilized) with a physiologically-acceptable carrier such as deionized water, saline, phosphate buffered saline, or the like. An additional optional component of the present vaccine is a pharmaceutically acceptable adjuvant. Non-limiting examples of suitable adjuvants include squalane and squalene (or other oils of animal origin); block copolymers such as Pluronic.RTM. (L121) Saponin; detergents such as Tween.RTM.-80; Quil.RTM. A, mineral oils such as Drakeol.RTM. or Marcol.RTM., vegetable oils such as peanut oil; Corynebacterium-derived adjuvants such as corynebacterium parvum; Propionibacterium-derived adjuvants such as Propionibacterium acne; Mycobacterium bovis (Bacillus Calmette and Guerinn, or BCG); interleukins such as interleukin 2 and interleukin-12; monokines such as interleukin 1; tumor necrosis factor; interferons such as gamma interferon; combinations such as saponin-aluminum hydroxide or Quil.RTM.-A aluminum hydroxide; liposomes; iscom adjuvant; mycobacterial cell wall extract; synthetic glycopeptides such as muramyl dipeptides or other derivatives; Avridine; Lipid A; dextran sulfate; DEAE-Dextran or DEAE-Dextran with aluminum phosphate; carboxypolymethylene, such as Carbopol.RTM.; ethylene malelic anhydride (EMA); acrylic copolymer emulsions such as Neocryl.RTM. A640 (e.g. U.S. Pat. No. 5,047,238); vaccinia or animal poxvirus proteins; subviral particle adjuvants such as orbivirus; cholera toxin; dimethyldiocledecylammonium bromide; or mixtures thereof.

Detailed Description Text (45):
Non-limiting examples of other suitable adjuvants include squalane and squalene (or other oils of animal origin); block copolymers such as Pluronic.RTM. (L121) Saponin; detergents such as Tween.RTM.-80; Quil.RTM. A, mineral oils such as Drakeol.RTM. or Marcol.RTM., vegetable oils such as peanut oil; Corynebacterium-derived adjuvants such as corynebacterium parvum; Propionibacterium-derived adjuvants such as Propionibacterium acne; Mycobacterium bovis (Bacillus Calmette and Guerinn, or BCG); interleukins such as interleukin 2 and interleukin-12; monokines such as interleukin 1; tumor necrosis factor, interferons such as gamma interferon; combinations such as saponin-aluminum hydroxide or Quil.RTM. -A aluminum hydroxide; liposomes; iscom adjuvant; mycobacterial cell wall extract; synthetic glycopeptides such as muramyl dipeptides or other derivatives; Avridine; Lipid A; dextran sulfate; DEAE-Dextran or DEAE-Dextran with aluminum phosphate; carboxypolymethylene, such as Carbopol.RTM.; EMA; acrylic copolymer emulsions such as Neocryl.RTM. A640 (e.g. U.S. Pat. No. 5,047,238); vaccinia or animal poxvirus proteins; subviral particle adjuvants such as orbivirus; cholera toxin; dimethyldiocledecylammonium bromide; or mixtures thereof. The composition may also include a non-ionic detergent or surfactant, preferably a polyoxyethylene sorbitan monooleate such as a Tween.RTM. detergent, most preferably Tween.RTM.-80, i.e. polyoxyethylene (20) sorbitan monooleate.

WEST

Generate Collection

L16: Entry 5 of 16 File: USPT Dec 21, 1999

DOCUMENT-IDENTIFIER: US 6004563 A
TITLE: Feline vaccine compositions and method for preventing chlamydia infections or diseases using the same

Detailed Description Text (24):
Ethylene/maleic anhydride copolymer is another preferred adjuvant. Suitable ethylene/maleic anhydride copolymers useful in this invention are the linear ethylene/maleic copolymers such as EMA-31 (as produced by Monsanto Co., St. Louis, Mo.), a copolymer with approximately equal amounts of ethylene and maleic anhydride, having an estimated average molecular weight of about 75,000 to 100,000. These copolymers are water soluble, white, free-flowing powders having the following typical properties: a true density of about 1.54 g/mL, a softening point of about 170.degree. C., a melting point of about 235.degree. C., a decomposition temperature of about 274.degree. C., a bulk density of about 20 lbs/ft.sup.3, and a pH (1% solution) of 2.3.